Hyperlipidemia: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 37: | Line 37: | ||
==Treatment== | ==Treatment== | ||
[[Hyperlipidemia medical therapy|Medical Therapy]] | [[Hyperlipidemia primary prevention|Primary Prevention]] | [[Hyperlipidemia secondary prevention|Secondary Prevention]] | [[Hyperlipidemia medical therapy|Medical Therapy]] | [[Hyperlipidemia primary prevention|Primary Prevention]] | [[Hyperlipidemia secondary prevention|Secondary Prevention]] | [[Hyperlipidemia cost-effectiveness of therapy|Cost-Effectiveness of Therapy]] | [[Hyperlipidemia future or investigational therapies|Future or Investigational Therapies]] | ||
==Case Studies== | ==Case Studies== | ||
Revision as of 02:35, 21 September 2012
For patient information click here Template:DiseaseDisorder infobox
|
Lipoprotein Disorders Microchapters |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Synonyms and keywords: Hyperlipidaemia,hyperlipoproteinemia
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Hyperlipidemia from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Screening tests | Screening frequency
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms | Physical Examination | Laboratory Findings
Treatment
Medical Therapy | Primary Prevention | Secondary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies